Zhang D
Nat Rev Drug Discov. 2025; .
PMID: 40038406
DOI: 10.1038/s41573-025-01145-0.
van Wier S, Beekman A
Chem Soc Rev. 2025; 54(4):1684-1698.
PMID: 39817557
PMC: 11736853.
DOI: 10.1039/d4cs00243a.
Yao H, Wu R, Du D, Ai F, Yang F, Li Y
Redox Rep. 2024; 30(1):2440204.
PMID: 39702961
PMC: 11703002.
DOI: 10.1080/13510002.2024.2440204.
Khramtsov Y, Ulasov A, Rosenkranz A, Slastnikova T, Lupanova T, Georgiev G
Pharmaceutics. 2024; 16(10).
PMID: 39458673
PMC: 11511107.
DOI: 10.3390/pharmaceutics16101345.
Silva-Llanes I, Martin-Baquero R, Berrojo-Armisen A, Rodriguez-Cueto C, Fernandez-Ruiz J, de Lago E
Antioxidants (Basel). 2024; 13(9).
PMID: 39334731
PMC: 11428793.
DOI: 10.3390/antiox13091072.
Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy.
Salloom R, Ahmad I, Sahtout D, Baine M, Abdalla M
Int J Mol Sci. 2024; 25(17).
PMID: 39273143
PMC: 11394971.
DOI: 10.3390/ijms25179195.
Molecular basis of the interactions between the disordered Neh4 and Neh5 domains of Nrf2 and CBP/p300 in oxidative stress response.
Karunatilleke N, Brickenden A, Choy W
Protein Sci. 2024; 33(9):e5137.
PMID: 39150085
PMC: 11328122.
DOI: 10.1002/pro.5137.
Targeting the AMPK/Nrf2 Pathway: A Novel Therapeutic Approach for Acute Lung Injury.
Huang Q, Ren Y, Yuan P, Huang M, Liu G, Shi Y
J Inflamm Res. 2024; 17:4683-4700.
PMID: 39051049
PMC: 11268519.
DOI: 10.2147/JIR.S467882.
Anti-Inflammatory Therapeutic Mechanisms of Isothiocyanates: Insights from Sulforaphane.
Habtemariam S
Biomedicines. 2024; 12(6).
PMID: 38927376
PMC: 11200786.
DOI: 10.3390/biomedicines12061169.
Biomarkers of NRF2 signalling: Current status and future challenges.
Morgenstern C, Lastres-Becker I, Demirdogen B, Costa V, Daiber A, Foresti R
Redox Biol. 2024; 72:103134.
PMID: 38643749
PMC: 11046063.
DOI: 10.1016/j.redox.2024.103134.
Ceramide kinase-mediated C1P metabolism attenuates acute liver injury by inhibiting the interaction between KEAP1 and NRF2.
Dong W, Li Q, Lu X, Lan J, Qiu Z, Wang X
Exp Mol Med. 2024; 56(4):946-958.
PMID: 38556546
PMC: 11059394.
DOI: 10.1038/s12276-024-01203-4.
The Potential Role of Major Argan Oil Compounds as Nrf2 Regulators and Their Antioxidant Effects.
El Kebbaj R, Bouchab H, Tahri-Joutey M, Rabbaa S, Limami Y, Nasser B
Antioxidants (Basel). 2024; 13(3).
PMID: 38539877
PMC: 10967919.
DOI: 10.3390/antiox13030344.
Inhibiting the Keap1/Nrf2 Protein-Protein Interaction with Protein-Like Polymers.
Carrow K, Hamilton H, Hopps M, Li Y, Qiao B, Payne N
Adv Mater. 2024; 36(21):e2311467.
PMID: 38241649
PMC: 11257647.
DOI: 10.1002/adma.202311467.
Exploring the multifaceted role of NRF2 in brain physiology and cancer: A comprehensive review.
Moubarak M, Pagano Zottola A, Larrieu C, Cuvellier S, Daubon T, Martin O
Neurooncol Adv. 2024; 6(1):vdad160.
PMID: 38221979
PMC: 10785770.
DOI: 10.1093/noajnl/vdad160.
Structural modification of C2-substituents on 1,4-bis(arylsulfonamido)benzene or naphthalene-N,N'-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction.
Lee S, Ali A, Abed D, Nguyen M, Verzi M, Hu L
Eur J Med Chem. 2023; 265:116104.
PMID: 38159482
PMC: 10794003.
DOI: 10.1016/j.ejmech.2023.116104.
Proximity proteomic analysis of the NRF family reveals the Parkinson's disease protein ZNF746/PARIS as a co-complexed repressor of NRF2.
LaPak K, Saeidi S, Bok I, Wamsley N, Plutzer I, Bhatt D
Sci Signal. 2023; 16(815):eadi9018.
PMID: 38085818
PMC: 10760916.
DOI: 10.1126/scisignal.adi9018.
Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases.
Jeong Y, Oh A, Jung Y, Gi H, Kim Y, Kim K
Exp Mol Med. 2023; 55(10):2097-2104.
PMID: 37779139
PMC: 10618535.
DOI: 10.1038/s12276-023-01087-w.
Forced Hepatic Expression of NRF2 or NQO1 Impedes Hepatocyte Lipid Accumulation in a Lipodystrophy Mouse Model.
Wakabayashi N, Yagishita Y, Joshi T, Kensler T
Int J Mol Sci. 2023; 24(17).
PMID: 37686150
PMC: 10487640.
DOI: 10.3390/ijms241713345.
Use of Deep-Learning Assisted Assessment of Cardiac Parameters in Zebrafish to Discover Cyanidin Chloride as a Novel Keap1 Inhibitor Against Doxorubicin-Induced Cardiotoxicity.
Liu C, Wang Y, Zeng Y, Kang Z, Zhao H, Qi K
Adv Sci (Weinh). 2023; 10(30):e2301136.
PMID: 37679058
PMC: 10602559.
DOI: 10.1002/advs.202301136.
A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.
Hammoutene A, Laouirem S, Albuquerque M, Colnot N, Brzustowski A, Valla D
JHEP Rep. 2023; 5(10):100845.
PMID: 37663119
PMC: 10472315.
DOI: 10.1016/j.jhepr.2023.100845.